The 340B Drug Pricing Program was created with a clear goal: to
allow hospitals to provide disadvantaged patients with health care.
In recent years, however, the program’s rapid growth has prompted
questions about whether 340B benefits patients. That growth, coupled
with a lack of charity care reporting and disclosure, has invited scrutiny of
the program.
